Virax Biolabs Group Limited Ordinary Shares Cash Flow-to-Debt Ratio
Virax Biolabs Group Limited Ordinary Shares cash flow-to-debt ratio. Virax Biolabs Group Limited Ordinary Shares (VRAX) has a Cash Flow-to-Debt Ratio of -4.56x as of September 2025, meaning its operating cash flow of $-2.92 Million could theoretically repay -5% of its total liabilities ($641.52K) in one year. See VRAX financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Virax Biolabs Group Limited Ordinary Shares (2020–2025)
Cash flow-to-debt ratio of Virax Biolabs Group Limited Ordinary Shares from 2020 to 2025. Historical debt coverage capacity for Virax Biolabs Group Limited Ordinary Shares across 6 annual periods. Also explore VRAX shareholders equity momentum to track the company's year-over-year net asset growth rate.
Virax Biolabs Group Limited Ordinary Shares Cash Flow-to-Debt Ratio by Year (2020–2025)
Virax Biolabs Group Limited Ordinary Shares cash flow-to-debt ratio by year from 2020 to 2025. Year-by-year debt coverage analysis for Virax Biolabs Group Limited Ordinary Shares. For the full cash flow conversion analysis, see Virax Biolabs Group Limited Ordinary Sha operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.73x | $-4.56 Million | $964.75K | ▲ +73.9% |
| 2024 | -18.10x | $-6.25 Million | $345.19K | ▼ -293.3% |
| 2023 | -4.60x | $-4.18 Million | $908.40K | ▼ -608.3% |
| 2022 | -0.65x | $-809.07K | $1.25 Million | ▲ +4.1% |
| 2021 | -0.68x | $-590.19K | $871.43K | ▼ -12.6% |
| 2020 | -0.60x | $-744.61K | $1.24 Million | — |